| 郭洪佩,范 俊,路臻豪,张爱霞,刘 伟.非布司他治疗老年高尿酸血症痛风患者的临床疗效及安全性分析[J].,2019,19(19):3780-3783 |
| 非布司他治疗老年高尿酸血症痛风患者的临床疗效及安全性分析 |
| Efficacy and Safety of Febuxostat in the Treatment of Elderly Patients with Hyperuricemia and Gout |
| 投稿时间：2019-03-21 修订日期：2019-04-18 |
| DOI：10.13241/j.cnki.pmb.2019.19.042 |
| 中文关键词: 痛风 高尿酸血症 非布司他 疗效 |
| 英文关键词: Gout Hyperuricemia Febuxostat Curative effect |
| 基金项目:上海市卫生和计生委支持项目(20134337) |
|
| 摘要点击次数: 563 |
| 全文下载次数: 511 |
| 中文摘要: |
| 摘要 目的：探究非布司他治疗老年高尿酸血症痛风患者的临床疗效及安全性。方法：选取我院2017年3月-2018年3月收治的高尿酸血症并发痛风患者60例，将其分为对照组和观察组，每组各30例。对照组采取苯溴马隆治疗，观察组采取非布司他进行治疗，对比两组患者的疗效和不良反应的发生情况。结果：治疗后，观察组患者治疗的总有效率为96.7%，显著高于对照组患者(80%，P＜0.05)；观察组患者的尿酸水平为(341.58±10.16) μmol/L，血沉水平变为(17.92±8.43) mm/h，均显著低于对照组患者[(341.58±10.16) μmol/L，(26.08±10.17) mm/h，P＜0.05]；观察组患者生活质量(quality of life，QOL)评分明显优于对照组患者(P＜0.05)；观察组患者只发生1例胃肠道反应，不良反应发生率为3.33%(1/30)，显著低于对照组[23.33%(7/30)，P＜0.05]。结论：与苯溴马隆相比，非布司他治疗老年高尿酸血症并痛风疗效更好，安全性更高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy and safety of febuxostat in the treatment of elderly patients with hyperuricemia and gout. Methods: 60 patients with hyperuricemia and gout were selected in our hospital from March 2017 to March 2018, and divided into the control group and the observation group for 30 patients each. The control group was treated with benzobromarone, and the observation group was treated with febuxostat. Then compare the efficacy and adverse reactions between the two groups. Results: After treatment, the total treatment effect ratio of the observation group was 96.7%, which was significantly higher than 80% of the control group (P<0.05). And the uric acid level of the observation group became (341.58±10.16) μmol/ L, the erythrocyte sedimentation level became (17.92±8.43) mm/h, which was significantly lower than that in the control group [(341.58±10.16) μmol/L, (26.08±10.17) mm/h, P<0.05]; The quality of life(QOL) scores of the observation group were significantly higher than the control group (P<0.05). Only one case of gastrointestinal reaction occurred in the observation group. The adverse reaction rate was 3.33% (1/30), which was significantly lower([23.33%(7/30), P<0.05]. Conclusion: Compared with benzbromarone, febuxostat is more effective and safer in treating elderly hyperuricemia with gout. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
